Real-life efficacy and tolerability profile of a similar biologic of adalimumab (zrc-3197) in patients with inflammatory arthritic conditions

Viswanath V. Kaushik

Rheumatology, Arthritis & Rheumatism Centre, Chennai, Tamilnadu India

Published in: BSR/Rheumatology, April/2018/57(3)
We share first-hand experience of the real life clinical efficacy and tolerability of this similar biologic adalimumab (hereafter ADA) in pts with RA and AS.

Patients with RA or AS treated with ADA at our OPD during the period of December 2014 to December 2016 were considered for this analysis. All pts were prescribed ADA 40mg s.c. every fortnight for 24 weeks. Standard efficacy outcomes and tolerability are reported using descriptive analyses and student’s T test.
## Result

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Baseline</th>
<th>Week 24</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AS patients (N=126)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BASDAI</td>
<td>7.08±0.52</td>
<td>2.15±0.67*</td>
</tr>
<tr>
<td>VAS</td>
<td>8.63±0.48</td>
<td>2.22±0.42*</td>
</tr>
<tr>
<td><strong>RA patients (N=83)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS 28</td>
<td>7.20±0.25</td>
<td>3.58±0.44*</td>
</tr>
<tr>
<td>VAS</td>
<td>8.61±0.64</td>
<td>2.24±0.68*</td>
</tr>
<tr>
<td>Mean±SD * p&lt;0.001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Result

• More than 200 patients - 126 with AS & 83 with RA received the ADA treatment for 24 weeks.

• About 95% of all patients experienced onset of symptomatic relief within 7 days of ADA initiation. 24 weeks of ADA therapy was associated with significant reductions in BASDAI, DAS28 and VAS (pain) scores (Table 1).

• About 36% & 58% pts in the AS group achieved BASDAI 50 & BASDAI 70 responses, respectively; and 96% pts were in remission or low disease activity (BASDAI < 4).

• In the RA group, 20% & 76% of patients achieved Good and Moderate EULAR responses, respectively on completion of 24 weeks of treatment. No serious adverse events were reported.
Conclusion

- This is a first-hand evidence on real-life clinical use of similar biologic of adalimumab (ZRC-3197) in a large group of patients with inflammatory arthritis. The clinical efficacy and tolerability profile shown by this similar biologic appears comparable to that reported of originator adalimumab.
Abridged Prescribing Information

COMPOSITION: Exemptia™ (Adalimumab) 40 mg /0.8 mL single use prefilled syringe and 20 mg /0.4 mL single use prefilled syringe

DESCRIPTION: EXEMPTIATM (Adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF-α). EXEMPTIATM is supplied as a sterile, preservative-free solution of Adalimumab for subcutaneous administration. The solution of EXEMPTIATM is clear and colorless.

MECHANISM OF ACTION: Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF-α receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Elevated levels of TNF-α is found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases.

INDICATIONS & DOSAGE: Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: The recommended dose of EXEMPTIATM for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg subcutaneously administered every other week. Methotrexate (MTX), other non-biologic DMARDs, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with EXEMPTIATM. Juvenile Idiopathic Arthritis: Exemptia™ dosing in JIA is based on weight; for 10 kg (22 lbs) to <15 kg (33 lbs): 10 mg s.c. every other week. For 15 kg (33 lbs) to < 30 kg (66 lbs): 20 mg s.c. every other week and for ≥ 30 kg (66 lbs): 40 mg s.c. every other week. Plaque Psoriasis or Non-Infectious Uveitis: Initial dose of 80 mg, followed by 40 mg every other week starting from week one after initial dose. Hidradenitis Suppurativa: 160 mg (Day 1) (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a maintenance dose of 40 mg every other week. Adult Crohn’s Disease and Ulcerative Colitis: Initial dose (Day 1): 160 mg s.c. (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days). Second dose two weeks later (Day 15): 80 mg. Two weeks later (Day 29): Begin a maintenance dose of 40 mg s.c. every other week. Pediatric Crohn’s Disease: For weight 17 kg (37 lbs) to < 40 kg (88 lbs): Initial dose (Day 1): 80 mg s.c. (two 40 mg injections in one day). Second dose two weeks later (Day 15): 40 mg s.c.. Two weeks later (Day 29): Begin a maintenance dose of 20 mg s.c. every other week. For ≥ 40 kg (88 lbs): Initial dose (Day 1): 160 mg s.c. (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days). Second dose two weeks later (Day 15): 80 mg s.c. (two 40 mg injections in one day). Two weeks later (Day 29): Begin a maintenance dose of 40 mg s.c. every other week.

CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients, Moderate to severe heart failure, Active tuberculosis or other severe infections such as sepsis and opportunistic infections. SPECIAL WARNINGS AND PRECAUTIONS: Serious and fungal infections: Do not start EXEMPTIATM during an active infection. If an infection develops, monitor carefully, and stop EXEMPTIATM if infection becomes serious. Anaphylaxis or serious allergic reactions may occur. Hepatitis B virus reactivation: Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop EXEMPTIATM and begin antiviral therapy. Demelinating disease: Exacerbation or new onset, may occur. Heart failure: Worsening or new onset, may occur. Lupus-like syndrome: Stop EXEMPTIATM if syndrome develops.

USE IN PREGNANCY AND LACTATION: Pregnancy Category B: Adequate and well controlled studies with EXEMPTIATM have not been conducted in pregnant women. Adalimumab is an IgG1 monoclonal antibody and IgG1 is actively transferred across the placenta during the third trimester of pregnancy. Lactation: No data is available on the absorption of adalimumab from breast milk in newborn or preterm infants. Caution should be exercised when EXEMPTIATM is administered to a nursing woman.

DRUG INTERACTION: Biological Products- Concomitant administration of EXEMPTIATM with other biologic DMARDs (e.g., Anakinra and Abatacept) or other TNF blockers is not recommended. Live Vaccines- Avoid the use of live vaccines with EXEMPTIATM. •Cytochrome P450 Substrates- The formation of CYP450 enzymes may be suppressed by increased levels of cytokines (e.g., TNFα, IL-6) during chronic inflammation. Upon initiation or discontinuation of EXEMPTIATM in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., Warfarin) or drug concentration (e.g., Cyclosporine or Theophylline) is recommended and the individual dose of the product may be adjusted as needed.

UNDESIRABLE EFFECTS: The most serious adverse reactions include the following: Serious Infections- Tuberculosis and Opportunistic Infections. Maligancies. The Clinical experience has reported Upper Respiratory Tract Infection (URTI), increased creatine phosphokinase, Headache, Rash, Sinusitis, Nausea, Urinary Tract Infection (UTI), Abdominal pain, Flu-like syndrome, Hyperlipidemia, Back pain, Hypercholesterolemia, Hematuria, Hypertension, increased alkaline phosphatase as common side effects.

STORAGE CONDITION: Store between + 2°C and + 8°C, in the carton to protect from light. Do not freeze Exemptia™. Do not use Exemptia™ if frozen, even if it has been thawed. Keep out of reach of children.

PRESENTATION: a) Injection: 40 mg/0.8 mL in a single-use prefilled syringe b) Injection: 20 mg/0.4 mL in a single-use prefilled syringe.

Please refer to the full Prescribing Information before starting EXEMPTIATM.
Please consult full Prescribing Information before prescribing.

Zydus Cadila does not recommend the use of any product in any different manner than as described in the prescribing information.

Further information is available on request from:

Cadila Healthcare Limited
Zydus Corporate Park
Nr. Vaishno Devi Circle,
SG Highway,
Ahmedabad – 382 481
Gujarat, India.
PHONE: +91-79-71800000
Thank you